Ophthalmology Products
Prior to starting Davio Pharma Consulting, Steve Davio, Ph.D. worked as Research Fellow for Bausch & Lomb on topical and injectable pharmaceutical products for eye health.

  • Davio led the CMC development team for Lotemax Gel®, a novel topical ophthalmic formulation containing non-settling drug particles, dispensed from a normal dropper bottle. This product is a gel at resting conditions, but a viscous fluid upon expression through a normal dropper tip.  The NDA belonging to Bausch & Lomb was approved Oct 2012 for post-operative inflammation of the eye.  The product was successfully launched in Jan 2013.
  • Davio and Marlowe publish “Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)”.  This paper demonstrates the benefit to the patient of non-settling drug particles. Marlowe and Davio, 2013; Clinical Ophthalmology 2014:8, 23-29.
  • Davio collaborated with University of Rochester Scientists Dr. James Aquavella MD and Dr. James Zavislan Ph.D. to measure tear film parameters in relation to dry eye and the application of over-the-counter eye drops.

Lotemax Gel®, is a registered trademark owned by Bausch & Lomb, Inc.